Streetbeat News

BMEA

Biomea Fusion, Inc.

Industry

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Open

7.02

Mkt cap

237M

Volume

907K

High

7.11

P/E Ratio

-1.62

52-wk high

22.74

Low

6.48

Div yield

N/A

52-wk low

3.61

Truist Securities analyst Robyn Karnauskas initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:39 pm

Alaska Air Group, Inc. (ALK) reported Q4 operating revenue of $2.55 billion, a 3% increase Y/Y, and an adjusted EPS of $0.30, beating consensus estimates. Shares rose 5.5%. Other stocks also saw gains, including Vera Therapeutics (VERA), AlTi Global (ALTI), and United Rentals (URI), following positive news such as earnings beats, analyst upgrades, and trial data. Xerox (XRX) and American Airlines (AAL) also moved higher after reporting their financial results.

Portfolio Pulse from Avi Kapoor

January 25, 2024 | 6:26 pm

Biomea Fusion, Inc. (NASDAQ:BMEA) presented at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting clinical progress and 2024 milestones. The company expects to complete the Phase II COVALENT-111 study for type 2 diabetes and the open label portion of the Phase II COVALENT-112 study for type 1 diabetes in 2024. Biomea Fusion reported positive data from previous trials and has received regulatory clearance to proceed with studies. The company is also advancing its oncology assets, with anticipated completion of dose escalation in studies for liquid and solid tumors, and acute leukemias. Additionally, Biomea Fusion is developing its FUSION™ Platform technology.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 4:04 pm

Jim Cramer, on CNBC's 'Mad Money Lightning Round,' advised investors to move on from Tidewater Inc. (TDW) due to its significant price movement. He endorsed Costco Wholesale Corporation (COST) as a great long-term investment, despite its occasional dips. Cramer preferred Realty Income Corporation (O) over Essential Properties Realty Trust, Inc. (EPRT) and recommended The Procter & Gamble Company (PG) over Unilever PLC (UL). He also suggested buying Biomea Fusion, Inc. (BMEA) as a speculative investment and expressed his liking for Cheniere Energy, Inc. (CNG). The article includes recent price actions of the mentioned stocks.

Portfolio Pulse from Avi Kapoor

January 03, 2024 | 2:01 pm

Biomea Fusion's stock is experiencing a rebound after a decline on Monday.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 8:48 pm

bluebird bio, Inc. (NASDAQ:BLUE) shares increased by 6.6% after presenting positive gene therapy data at the ASH Annual Meeting. Other stocks experienced significant movement in Monday's mid-day session, with notable gainers including Pasithea Therapeutics Corp. (NASDAQ:KTTA), NextPlay Technologies, Inc. (NASDAQ:NXTP), and MorphoSys AG (NASDAQ:MOR). The Cigna Group (NYSE:CI) shares rose after withdrawing from a merger with Humana Inc. (NYSE:HUM), and Macy's, Inc. (NYSE:M) increased on news of a buyout bid. Conversely, Near Intelligence, Inc. (NASDAQ:NIR) and Troika Media Group, Inc. (NASDAQ:TRKA) fell sharply due to bankruptcy filings, while Altamira Therapeutics Ltd. (NASDAQ:CYTO) dropped after announcing a reverse stock split. Cryptocurrency-related stocks like Marathon Digital Holdings, Inc. (NASDAQ:MARA) and Riot Platforms, Inc. (NASDAQ:RIOT) declined alongside a drop in Bitcoin's price.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 6:13 pm

Health care stocks experienced significant movement in Monday's intraday session. Pasithea Therapeutics (KTTA) saw a 105.9% increase, while Cogent Biosciences (COGT) declined by 53.5%. Other notable gainers include Assure Hldgs (IONM), Marker Therapeutics (MRKR), MorphoSys (MOR), G1 Therapeutics (GTHX), and Cognition Therapeutics (CGTX). On the losing side, alongside COGT, were Altamira Therapeutics (CYTO), X4 Pharmaceuticals (XFOR), Jaguar Health (JAGX), Biomea Fusion (BMEA), and Vapotherm (VAPO).

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 5:30 pm

Biomea Fusion, Inc. (NASDAQ:BMEA) shares have declined by nearly 40% over the past five days, continuing a downward trend. The company presented clinical data for BMF-219 at the American Society of Hematology Annual Meeting and will detail Phase II study results in March 2024. Despite meaningful HbA1c reductions in patients, the stock has attracted significant short interest, with 44.9% of BMEA shares sold short.

Portfolio Pulse from Erica Kollmann

December 11, 2023 | 4:30 pm

On Monday, several stocks experienced declines, with notable losses in the biotech sector and among companies associated with Bitcoin due to a pullback in its price. Cogent Biosciences and Biomea Fusion reported clinical trial data, resulting in significant drops in their share prices. Companies like CleanSpark, HIVE Digital Technologies, Riot Platforms, and Marathon Digital Holdings were affected by the Bitcoin price movement. Gildan Activewear announced a leadership change, and Tellurian updated its executive team.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 4:07 pm

Biomea Fusion's stock price dropped following the announcement of data presentation for BMF-219 targeting relapsed/refractory AML patients with menin-dependent mutations at ASH 2023.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 3:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.